Medtronic expands diabetes tech access with Medicare coverage, FDA clearances

Medtronic, a global leader in medical technology, has expanded access to its advanced diabetes management technologies through new Medicare coverage and FDA clearances. The company announced on March 15, 2024, that its MiniMed 780G system, an advanced hybrid closed-loop insulin pump, has received FDA clearance and is now covered by Medicare, making it more accessible to a broader range of patients. This development comes as part of Medtronic's ongoing efforts to improve diabetes care and reduce the burden of the disease on patients. The MiniMed 780G system is designed to automatically adjust insulin delivery based on continuous glucose monitoring, providing more precise and personalized diabetes management. This expansion in coverage and clearance is expected to benefit thousands of Medicare beneficiaries who rely on advanced diabetes technologies for better health outcomes. Medtronic's initiative aligns with broader trends in healthcare, where technology and insurance policies are increasingly converging to enhance patient care and accessibility. The company's commitment to innovation and patient-centric solutions underscores its leadership in the medical technology sector.